Get the Stockscreener App
4.63
4.28%
0.19
After Hours:
4.62
-0.010
-0.22%
Evolus Inc stock is traded at $4.63, with a volume of 542.32K.
It is up +4.28% in the last 24 hours and down -7.58% over the past month.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
See More
Previous Close:
$4.44
Open:
$4.47
24h Volume:
542.32K
Relative Volume:
0.44
Market Cap:
$301.23M
Revenue:
$297.18M
Net Income/Loss:
$-51.64M
P/E Ratio:
-5.7637
EPS:
-0.8033
Net Cash Flow:
$-50.72M
1W Performance:
+13.20%
1M Performance:
-7.58%
6M Performance:
-29.95%
1Y Performance:
-54.74%
1-Day Range:
$4.38
$4.64
1-Week Range:
$4.015
$4.64
52-Week Range:
$3.86
$12.28
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
4.63 | 288.87M | 297.18M | -51.64M | -50.72M | -0.8033 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 56.39B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
120.76 | 50.93B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.66 | 43.19B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.61 | 36.99B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
577.58 | 25.36B | 3.18B | 1.33B | 1.04B | 27.90 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Downgrade | Needham | Buy → Hold |
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Evolus to Report First Quarter Financial Results on May 4, 2026 - Yahoo Finance
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 earnings call transcript - MSN
Aug Big Picture: What analysts say about Evolus Inc stockQuarterly Investment Review & AI Based Trade Execution Alerts - baoquankhu1.vn
Bank Watch: What is the earnings history of Evolus Inc2026 Reactions & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Evolus and Oramed Pharmaceuticals Compared - National Today
Evolus boosts balance sheet with lower-cost refinancing and flexibility - MSN
How The Evolus (EOLS) Investment Story Is Shifting After Softer Guidance And Target Cuts - Yahoo Finance
Evolus (LTS:0K16) PB Ratio : (As of Apr. 10, 2026) - GuruFocus
Street Watch: Is Evolus Inc showing insider buying2026 PostEarnings & Real-Time Buy Signal Notifications - baoquankhu1.vn
EOLS Stock Price, Quote & Chart | EVOLUS INC (NASDAQ:EOLS) - ChartMill
Tech Rally: Is Evolus Inc undervalued by DCF analysisQuarterly Earnings Report & Verified Swing Trading Watchlists - baoquankhu1.vn
Winners Losers: Is Evolus Inc showing insider buying2026 EndofMonth & Breakout Confirmation Trade Signals - baoquankhu1.vn
FY2026 Earnings Forecast for Evolus Issued By HC Wainwright - MarketBeat
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference - BioSpace
Market Leaders: What analysts say about Evolus Inc stockWeekly Investment Recap & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Evolus Inc (EOLS) Stock Price Quote Today & Current Price Chart - Capital.com
Evolus, Inc. (NASDAQ:EOLS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Death Cross: Should you avoid Evolus Inc stock right now2026 Fed Impact & High Return Stock Watch Alerts - baoquankhu1.vn
US Market Wrap: What hedge funds are buying Evolus Inc2026 Gainers & Consistent Return Strategy Ideas - baoquankhu1.vn
Vanguard disaggregates holdings for Evolus (NASDAQ: EOLS) after internal realignment - Stock Titan
Evolus, Inc.(NasdaqGM: EOLS) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Evolus (NASDAQ:EOLS) Insider David Moatazedi Sells 13,669 Shares - MarketBeat
Evolus (NASDAQ:EOLS) Insider Rui Avelar Sells 3,119 Shares - MarketBeat
Avelar Rui sells Evolus (EOLS) shares worth $14815 By Investing.com - Investing.com Canada
Evolus CEO Moatazedi sells $64929 in shares By Investing.com - Investing.com Australia
Evolus CEO Moatazedi sells $64929 in shares - Investing.com
Avelar Rui sells Evolus (EOLS) shares worth $14815 - Investing.com
Evolus (EOLS) officer tax-driven sale of 3,119 shares under 10b5-1 plan - Stock Titan
Evolus (NASDAQ: EOLS) insider sells 13,669 shares to cover taxes - Stock Titan
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock By Investing.com - Investing.com South Africa
Evolus CEO Moatazedi sells $570k in shares By Investing.com - Investing.com India
Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells 29,996 Shares of Stock - MarketBeat
David Moatazedi Sells 116,720 Shares of Evolus (NASDAQ:EOLS) Stock - MarketBeat
Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock - Investing.com Australia
Evolus CEO Moatazedi sells $570k in shares - Investing.com
Evolus (EOLS) executive sells 29,996 shares after PSU vesting - Stock Titan
(EOLS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Dip Buying: What is the earnings history of Evolus IncMarket Sentiment Review & Safe Entry Point Identification - baoquankhu1.vn
Evolus plunges after Q2 miss, guidance cut; Needham downgrades - MSN
Jobs Data: Whats the beta of Evolus Inc stockTrade Entry Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Divisadero Street Capital Management LP Makes New $2.38 Million Investment in Evolus, Inc. $EOLS - MarketBeat
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference - Yahoo Finance
Evolus (NASDAQ:EOLS) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
Evolus, Inc. Files Form 8-K Announcing Executive Changes and Company Information (March 13, 2026) - Minichart
Evolus reclassifies Vikram Malik to Class II director to balance board - Investing.com
Evolus reclassifies Vikram Malik to Class II director to balance board By Investing.com - Investing.com India
Vikram Malik reclassified to Class II director at Evolus - TradingView
Evolus (EOLS) reclassifies chairman Vikram Malik to restore board balance - Stock Titan
Evolus, Inc. Announces Executive Changes, Effective March 13, 2026 - marketscreener.com
How The Narrative On Evolus (EOLS) Is Resetting After Cautious 2025 And 2026 Guidance - Yahoo Finance
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Evolus Inc Stock (EOLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MOATAZEDI DAVID | See Remarks |
Mar 20 '26 |
Sale |
4.75 |
13,669 |
64,929 |
604,700 |
| MOATAZEDI DAVID | See Remarks |
Mar 16 '26 |
Option Exercise |
0.00 |
67,489 |
0 |
735,089 |
| MOATAZEDI DAVID | See Remarks |
Mar 17 '26 |
Sale |
4.89 |
116,720 |
570,562 |
618,369 |
| Avelar Rui | See Remarks |
Mar 16 '26 |
Option Exercise |
0.00 |
8,804 |
0 |
460,538 |
| Avelar Rui | See Remarks |
Mar 17 '26 |
Sale |
4.89 |
29,996 |
146,629 |
430,542 |
| MOATAZEDI DAVID | See Remarks |
Dec 22 '25 |
Sale |
7.15 |
10,539 |
75,361 |
354,388 |
| Avelar Rui | See Remarks |
Dec 22 '25 |
Sale |
7.15 |
2,261 |
16,168 |
356,821 |
| Yamagishi-Dressler Tomoko | Chief Marketing Officer |
Aug 22 '25 |
Sale |
7.51 |
5,722 |
42,972 |
89,949 |
| Stewart Brady | Director |
Aug 15 '25 |
Buy |
6.82 |
30,000 |
204,486 |
88,629 |
| MOATAZEDI DAVID | See Remarks |
Jun 13 '25 |
Sale |
10.05 |
111,323 |
1,119,141 |
381,509 |
1.45%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):